Immunogenicity and Safety of Adjuvanted SCB-2020S Vaccines in Adults

COVID-19 Clinical Trial

Official title:

An Observer-blind, Randomized, Controlled, Phase 2 Study to Evaluate the Immunogenicity and Safety of Clover Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Subunit Vaccine (SCB-2020S) in Adults

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT04950751
• Other study ID #: CLO-SCB-2020-001
• Status: Withdrawn
• Phase: Phase 2
• Start date: August 2021
• Est. completion date: April 2022

Study information

• Verified date: September 2021
• Source: Clover Biopharmaceuticals AUS Pty Ltd
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a phase 2, randomized, controlled, observer-blind study to evaluate the immunogenicity and safety of different formulations of the investigational adjuvanted recombinant SARS-CoV-2 trimeric S-protein (from B.1.351 variant) subunit vaccine (SCB-2020S), when administered as 2-dose vaccination series 21 days apart to adults ≥ 18 years of age.

Description:

Clover has developed a second candidate vaccine, SCB-2020S, that contains S protein from the dominant B.1.351 variant. The purpose of clinical study CLO-SCB-2020-001 is to assess the immunogenicity and safety of different formulations of the SCB-2020S compared to the prototype SCB-2019 vaccine, and to select a formulation of SCB-2020S for further clinical development. The protocol plans to enroll 150 participants. There will be 5 study arms and participants will receive two intramuscular (i.m.) injections, one at Day 1 and one at Day 22.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: April 2022
• Est. primary completion date: April 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• 1. Male or female =18 years of age
• 2. Individuals are willing and able to comply with study requirements, including all scheduled visits, vaccinations, laboratory tests and other study procedures.
• 3.Individuals are willing and able to give an informed consent, prior to screening
• 4. Healthy participants or participants with pre-existing medical conditions* who are in a stable medical condition. (*A stable medical condition is defined as disease not requiring significant change or hospitalization for worsening disease during the 3 months before enrollment.)
• 5. Female participants of childbearing potential may be enrolled in the study, if the participant has practiced adequate contraception for 30 days prior to vaccination and has a negative pregnancy test on the day of vaccination and has agreed to continue adequate contraception for 3 months after the last vaccination
• 6. Male participants must agree to employ acceptable contraception from the day of the first dose of the study vaccine until 6 months after the last dose of the study vaccine and also refrain from donating sperm during this period.

Exclusion Criteria:

• 1. Individuals with body temperature >37.5°C (axillary), or any acute illness at baseline (Day 1) or within 3 days prior to randomization. Participants meeting this criterion may be rescheduled within the relevant window. Febrile participants with minor illnesses can be enrolled at the discretion of the investigator.
• 2. Individuals with laboratory-confirmed SARS-CoV-2 infection [as defined by reverse transcriptase polymerase chain reaction (RT-PCR) assay or Rapid COVID Antigen Test or an equivalent at Visit 1] or with history of COVID-19.
• 3. Individuals seropositive at Baseline for SARS-CoV-2.
• 4.Individuals who have received an investigational or authorized COVID-19 vaccine prior to Day 1, or plan to receive COVID-19 vaccine during the study period.
• 5. Any confirmed or suspected immunosuppressive or immunodeficient condition resulting from disease [e.g., malignancy, human immunodeficiency virus (HIV) infection] or immunosuppressive/cytotoxic therapy (e.g., systemic corticosteroids, medications used for cancer chemotherapy, organ transplantation or to treat autoimmune disorders) within 3 months prior to Day 1.
• 6. Individuals with any progressive unstable or uncontrolled clinical conditions.
• 7. Individuals who are pregnant, or breastfeeding, or planning to become pregnant while enrolled in this study or during the study period.
• 8. Individuals who have a history of severe adverse reaction associated with a vaccine or severe allergic reaction [e.g., anaphylaxis to any component of the study vaccines (CpG 1018, aluminum), or SCB-2020S/SCB-2019 components ].
• 9. Individuals who have a history of malignancy within 1 year before screening (exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix which have been cured, or other malignancies with minimal risk of recurrence).
• 10. Individuals who have received any other investigational product within 30 days prior to Day 1 or intend to participate in another clinical study at any time during the conduct of this study.
• 11. Individuals who have received any other licensed vaccines within 14 days prior to enrollment in this study or who are planning to receive any vaccine up to 21 days after the second vaccination.
• 12. Individuals with known bleeding disorder that would, in the opinion of the investigator, contraindicate intramuscular injection.
• 13. Individuals who have received treatment with Rituximab or any other anti-CD20 monoclonal antibodies within 9 months prior to Day 1 or planned during the study period.
• 14. Administration of intravenous immunoglobulins and/or any blood products within 3 months prior to enrollment or planned administration during the study period.
• 15. Individuals with positive test result for hepatitis B surface antigen, hepatitis C virus antibody, or human immunodeficiency virus types 1 or 2 antibodies at Screening.
• 16. Individuals with safety laboratory test results (hematology, chemistry, and coagulation) with a toxicity score of Grade =2 at Screening (see Laboratory Manual for laboratory-specific normal ranges and associated toxicity grades). The inclusion of subjects with non-clinically significant (NCS) Grade 1 laboratory abnormalities is allowed based on the Investigator's discretion.
• 17. The subject has a reported or documented history of alcohol abuse or drug addiction or nonmedicinal recreational drug use (excluding nonprescription health supplements and herbal remedies) within 1 year before the planned day of dose administration.
• 18. The subject has a positive test result for drugs of abuse at Screening.
• 19. Individuals with any condition that, in the opinion of the investigator, would interfere with the primary study objectives or pose additional risk to the participant.

Related Conditions & MeSH terms

• COVID-19

Intervention

Biological:
• candidate vaccine, SCB-2020S
a recombinant SARS-Co-2 trimeric S-protein (from B.1.351 variant) subunit vaccine for COVID-19

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Clover Biopharmaceuticals AUS Pty Ltd

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Geometric mean titer (GMT) of SARS-CoV-2 neutralising antibodies to B.1.351 variant		Days 36
Primary	Proportion of subjects achieving seroconversion of SARS-CoV-2 neutralising antibodies to B.1.351 variant	Seroconversion rate (percentage of participants with a =4-fold increase in titer from that at Day 1 (or from LLoQ if Day 1 titer	Day 36
Primary	Geometric mean fold rise (GMFR) of SARS-Cov-2 neutralising antibodies to B.1.351 variant		Day 36/Day 1
Secondary	Geometric mean titer (GMT) of SARS-CoV-2 neutralising antibodies to Wuhan strain		Day 36
Secondary	Proportion of subjects achieving seroconversion of SARS-CoV-2 neutralising antibodies to Wuhan strain	Seroconversion rate (percentage of participants with a =4-fold increase in titer from that at Day 1 (or from LLoQ if Day 1 titer	Day 36
Secondary	Geometric mean fold rise (GMFR) of SARS-Cov-2 neutralising antibodies to Wuhan strain		Day 36/Day 1
Secondary	Geometric mean titer (GMT) of antibody titers specific to SCB-2019 antigen		Day 36
Secondary	Proportion of subjects achieving seroconversion of antibodies specific to SCB-2019	Seroconversion rate (percentage of participants with a =4-fold increase in titer from that at Day 1 (or from LLoQ if Day 1 titer	Day 36
Secondary	Geometric mean fold rise (GMFR) of antibodies specific to SCB-2019		Day 36/Day 1
Secondary	Geometric mean titer (GMT) of SARS-CoV-2 neutralising antibodies to B.1.351 variant		Day 205
Secondary	Proportion of subjects achieving seroconversion of SARS-CoV-2 neutralising antibodies to B.1.351 variant	Seroconversion rate (percentage of participants with a =4-fold increase in titer from that at Day 1 (or from LLoQ if Day 1 titer	Day 205
Secondary	Geometric mean fold rise (GMFR) of SARS-Cov-2 neutralising antibodies to B.1.351 variant		Day 205/Day 1
Secondary	Geometric mean titer (GMT) of SARS-CoV-2 neutralising antibodies to Wuhan strain		Day 205
Secondary	Proportion of subjects achieving seroconversion of SARS-CoV-2 neutralising antibodies to Wuhan strain	Seroconversion rate (percentage of participants with a =4-fold increase in titer from that at Day 1 (or from LLoQ if Day 1 titer	Day 205
Secondary	Geometric mean fold rise (GMFR) of SARS-Cov-2 neutralising antibodies to Wuhan strain		Day 205/Day 1
Secondary	Geometric mean titer (GMT) of antibody titers specific to SCB-2019 antigen		Day 205
Secondary	Proportion of subjects achieving seroconversion of antibodies specific to SCB-2019	Seroconversion rate (percentage of participants with a =4-fold increase in titer from that at Day 1 (or from LLoQ if Day 1 titer	Day 205
Secondary	Geometric mean fold rise (GMFR) of antibodies specific to SCB-2019		Day 205/Day 1
Secondary	Reactogenicity of the vaccines as indicated by the occurrence of solicited local reactions and solicited systemic adverse events.	Percentage of participants with local injection site reactions (pain, redness, swelling) and systemic adverse events (fatigue, headache, myalgia, arthralgia, loss of appetite, nausea, chills, and fever)	7 days after each dose
Secondary	Safety of the vaccines in terms of the occurrence of unsolicited adverse events	Percentage of participants with any adverse event other that those listed above as solicited adverse events	Up to 21 days after second dose (Day 43)
Secondary	Safety of the vaccines in terms of the occurrence of medically attended adverse events (MAAEs), serious adverse events (SAEs), adverse events leading to discontinuation from study, and adverse events of special interest (AESI).	Percentage of participants with any adverse events in this category	through study completion, an average of 7 months
Secondary	Proportion of subjects with abnormal markers of hematology, biochemistry and coagulation parameters		Day 29